NRSN

0.8385

5.79% -0.0515

Dopo l'orario di chiusura: .83 -0.0085 -1.01%

Neurosense Therapeutics Ltd (NRSN)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

$0.89

Aprire:

$0.87

Volume 24 ore:

409.51K

Relative Volume:

1.25

Capitalizzazione di mercato:

$24.90M

Reddito:

Utile/perdita netta:

$-10.21M

Rapporto P/E:

-1.4353

EPS:

-0.5842

Flusso di cassa netto:

1 W Prestazione:

-15.30%

1M Prestazione:

-14.67%

6M Prestazione:

-64.77%

1 anno Prestazione:

-2.50%

Intervallo 1D:

$0.82

$0.90

Intervallo di 1 settimana:

$0.82

$0.9999

Portata 52W:

$0.81

$2.60

Neurosense Therapeutics Ltd Stock (NRSN) Company Profile

Nome

Neurosense Therapeutics Ltd

Settore

Healthcare (1131)

Industria

Biotechnology (631)

Telefono

Indirizzo

Dipendente

Cinguettio

Prossima data di guadagno

2025-11-26

Ultimi documenti SEC

NRSN's Discussions on Twitter

Confronta NRSN con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NRSN Neurosense Therapeutics Ltd	0.8385	26.43M	0	-10.21M	0	-0.5842
VRTX Vertex Pharmaceuticals Inc	455.71	114.69B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	752.62	77.91B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	850.95	54.05B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	391.50	52.52B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	196.92	42.02B	447.02M	-1.18B	-906.14M	-6.1812

Neurosense Therapeutics Ltd Borsa (NRSN) Ultime notizie

Dec 13, 2025

Wall Street Zen Downgrades NeuroSense Therapeutics (NASDAQ:NRSN) to Sell - Defense World

Dec 13, 2025

Dec 09, 2025

Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - Yahoo Finance

Dec 09, 2025

A better buy-in window may exist right now for Lexicon Pharmaceuticals Inc (LXRX) - setenews.com

Dec 09, 2025

Dec 08, 2025

NRSN: PARAGON phase III ALS trial starts mid-2026, with strong data, FDA clearance, and global scope - TradingView — Track All Markets

Dec 08, 2025

NRSN: Global phase III ALS trial set for mid-2026, with strong efficacy and active partnership talks - TradingView — Track All Markets

Dec 08, 2025

NeuroSense Completes Data Collection for Alzheimer’s Trial - TipRanks

Dec 08, 2025

NeuroSense (NRSN) locks RoAD Phase 2 Alzheimer’s trial database, eyes Q1 2026 data - Stock Titan

Dec 08, 2025

NeuroSense completes data collection for Alzheimer’s trial - MSN

Dec 08, 2025

Dec 05, 2025

Will NeuroSense Therapeutics Ltd. (H1Z) stock outperform value peersEarnings Summary Report & Daily Oversold Stock Bounce Ideas - Newser

Dec 05, 2025

How strong is NeuroSense Therapeutics Ltd. Equity Warrant stock balance sheetMarket Performance Report & Verified Short-Term Trading Plans - Newser

Dec 05, 2025

Dec 04, 2025

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 - Nasdaq

Dec 04, 2025

NeuroSense Therapeutics LtdResuming regulatory advancement in Canada for PrimeC in amyotrophic lateral sclerosis - marketscreener.com

Dec 04, 2025

NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Drug - TipRanks

Dec 04, 2025

Neurosense Therapeutics LtdResuming Regulatory Advancement In Canada For Primec In Amyotrophic Lateral Sclerosis - TradingView

Dec 04, 2025

NeuroSense (NASDAQ: NRSN) plans April 2026 Health Canada pre-NDS as it eyes mid-2026 NDS - Stock Titan

Dec 04, 2025

Is NeuroSense Therapeutics Ltd. stock overvalued by current metricsMarket Growth Review & Capital Protection Trading Alerts - Newser

Dec 04, 2025

How interest rate cuts could boost NeuroSense Therapeutics Ltd. Equity Warrant stockWeekly Trade Summary & AI Enhanced Trade Execution Alerts - Newser

Dec 04, 2025

Dec 03, 2025

NeuroSense Therapeutics (NRSN) Stock Analysis Report | Financials & Insights - Benzinga

Dec 03, 2025

Dec 02, 2025

What downside risks could hit NeuroSense Therapeutics Ltd. (H1Z) stockPortfolio Value Summary & Risk Managed Investment Signals - Newser

Dec 02, 2025

Dec 01, 2025

Aug EndMonth: How NeuroSense Therapeutics Ltd stock compares to growth peersWeekly Investment Report & Risk Managed Investment Strategies - BỘ NỘI VỤ

Dec 01, 2025

Nov 29, 2025

Is NeuroSense Therapeutics Ltd H1Z a good long term investmentMean Reversion Trades & High Return Capital Strategies - earlytimes.in

Nov 29, 2025

Nov 28, 2025

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers (PR Newswire) - Aktiellt

Nov 28, 2025

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community (PR Newswire) - Aktiellt

Nov 28, 2025

Nov 27, 2025

Hedge Fund Moves: How NeuroSense Therapeutics Ltd. stock compares to growth peers2025 Bull vs Bear & Proven Capital Preservation Methods - moha.gov.vn

Nov 27, 2025

Nov 25, 2025

NeuroSense Therapeutics (NASDAQ:NRSN) Given “Buy” Rating at D. Boral Capital - Defense World

Nov 25, 2025

NeuroSense Gains FDA Approval for Phase 3 ALS Trial - MSN

Nov 25, 2025

Prepare Yourself for Liftoff: NeuroSense Therapeutics Ltd (NRSN) - setenews.com

Nov 25, 2025

Nov 24, 2025

D. Boral Capital Maintains NeuroSense Therapeutics (NRSN) Buy Recommendation - Nasdaq

Nov 24, 2025

NeuroSense receives FDA clearance to initiate pivotal phase 3 trial for PrimeC in ALS - marketscreener.com

Nov 24, 2025

NeuroSense Therapeutics (NRSN) Maintains 'Buy' Rating and $14 Ta - GuruFocus

Nov 24, 2025

NeuroSense Therapeutics Cleared by FDA to Initiate Phase 3 Trial for PrimeC to Treat ALS - marketscreener.com

Nov 24, 2025

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS - Barchart.com

Nov 24, 2025

Nov 21, 2025